31
FUMARATE ESTER DOSAGE FORMS. March 2, 2017: US20170056360-A1

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One e ...


32
FUMARATE ESTER DOSAGE FORMS. March 2, 2017: US20170056359-A1

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One e ...


33
FUMARATE ESTER PHARMACEUTICAL COMPOSITIONS. March 16, 2017: US20170071891-A1

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising fumarate esters are described.


34
METHOD OF REMOVING AN INFLATED IMPLANT FROM A BLADDER. March 9, 2017: US20170065160-A1

An inflated implant, such as an attenuation device, previously implanted in a urinary bladder can later be removed according to a number of different methods. Preferably, removal is accomplished transurethrally. In one embodiment, removal is accomplished by reducing the inflated implant from an enla ...


35
METHOD OF REMOVING AN INFLATED IMPLANT FROM A BLADDER. March 23, 2017: US20170079761-A1

An inflated implant, such as an attenuation device, previously implanted in a urinary bladder can later be removed according to a number of different methods. Preferably, removal is accomplished transurethrally. In one embodiment, removal is accomplished by reducing the inflated implant from an enla ...


36
FUMARATE ESTER PHARMACEUTICAL COMPOSITIONS. April 13, 2017: US20170100360-A1

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral pharmaceutical compositions comprising fumarate esters are described.


37
FUMARATE ESTER DOSAGE FORMS. April 13, 2017: US20170100361-A1

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One e ...


38
FUMARATE ESTER DOSAGE FORMS. April 13, 2017: US20170100362-A1

Described herein are pharmaceutical compositions comprising fumarate esters, methods for making the same, and methods for treating subjects in need thereof. In particular, oral controlled release pharmaceutical compositions comprising fumarate esters suspended in liquid matrices are described. One e ...


39
LIQUID FORMULATION OF A FUSION PROTEIN COMPRISING TNFR AND FC REGION. February 2, 2017: US20170028020-A1

The present invention relates to a liquid formulation comprising a TNFR-Fc fusion protein and a stabilizer, in which the fusion protein comprises TNFR (tumor necrosis factor receptor) or a fragment thereof and an immunoglobulin Fc region, and the stabilizer comprises one or more amino acids selected ...


40
BIOFILM PREVENTION, DISRUPTION AND TREATMENT WITH BACTERIOPHAGE LYSIN. May 11, 2017: US20170127683-A1

The present invention provides methods for the prevention, control, disruption and treatment of bacterial biofilms with lysin, particularly lysin having capability to kill Staphylococcal bacteria, including drug resistant Staphylococcus aureus, particularly the lysin PlySs2. The invention also provi ...



Click the thumbnails below to visualize the patent trend.